Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
  • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• This invention relates to novel 1,4-dihydropyridine-3,5-dicarboxylate derivatives, and more specifically to 1,4-dihydropyridine-3,5-dicarboxylate derivatives each of which is represented by the following general formula (I): ##STR5## wherein R means is imidazolyl or pyridyl group, R 1 denotes a hydrogen or halogen atom or a nitro or trifluoromethyl group, R 2 is a lower alkyl group, X is CH or N, A means a lower alkylene group, ##STR6## B being a lower alkylene or O-lower alkylene group, ##STR7## R 4 being a hydrogen atom or lower alkyl group, or ##STR8## m denotes a number of 1-3, and n stands for 1 or 2.
• 1,4-dihydropyridine-3,5-dicarboxylic acid have pharmacological effects such as vasodilative effects.
• a variety derivatives of 1,4-dihydropyridine-3,5-dicarboxylic acid have heretofore been synthesized, pharmacological effects of which have also been studied.
• nifedipine Vater, W. et al, Arzneim. Forsch., 22, 1(1972)
• nicardipine Takenaka, T. et al, Arzneim. Forsch., 26, 2172(1976)] have already been put as pharmaceutical products on the market.
• the compounds (I) of this invention have vasodilative effects, hyperkinemic effects, platelet aggregation inhibitory effects, thromboxane A 2 formation inhibitory effects and so on, and are hence useful as pharmaceutical products such as vasodilators, antihypertensives, antithrombotic agents, anti-arteriosclerotic agents, etc.
• the compounds (I) of this invention are advantageous particularly as therapeutic agents for arteriosclerosis as they have both coronary hyperkinemic effects and thromboxane A 2 formation inhibitory effects.
• the compounds (I) of this invention have such advantageous features that they show hyperkinemic effects for the coronary artery and vertebral artery over longer periods of time and weaker heart-beat increasing effects.
• the compounds (I) of this invention can be prepared, for example, in accordance with any one of the following Processes A-D:
• A-1 is the Hantzsch Pyridine Synthesis while Processes A-2-A-7 are its modifications.
• the reactions of Process A-1-A-7 may be effected by heating their respective reactants in a solvent or without using any solvent, at 30°-180° C. or preferably 50°-130° C. and for 2-24 hours.
• a solvent it is possible to use a lower alcohol such as ethanol, propanol, isopropanol or n-butanol, a halogenated hydrocarbon such as chloroform, dichloroethane or trichloroethane, benzene, pyridine or the like.
• the compound (I) of this invention can be prepared.
• This reaction may be carried out by reacting the compound (IX) with N,N'-carbonyldiimidazole and then with the compound (X), for example, in an inert solvent.
• DBU 1,8-diazabicyclo-[5.4.0]-7-undecene
• the inert solvent may be used tetrahydrofuran, dioxane, chloroform, methylene chloride, N,N-dimethylformamide, dimethyl sulfoxide, or the like.
• the reaction is allowed to proceed by stirring the reactants for 1-24 hours at room temperature or an elevated temperature, thereby to provide the compound (I).
• the compound (I) may also be obtained by converting the compound (IX) into its corresponding acid halide in a manner known per se in the art and then reacting the acid halide further with the compound (X).
• the compound (IX), one of the starting compounds, has already been known [Chem. Pharm. Bull., 27, 1426(1979)], and may be prepared by various processes.
• the compound (I) of this invention can be prepared.
• This reaction may be effected, for example, in an inert solvent and in the presence of a dehydrating agent such as dicyclohexylcarbodiimide (DCC) or the like.
• a dehydrating agent such as dicyclohexylcarbodiimide (DCC) or the like.
• DCC dicyclohexylcarbodiimide
• Upon conducting the reaction it is feasible to use 4-dimethylaminopyridine, 4-pyrrolidinopyridine or the like as a reaction accelerator.
• one of the starting compounds, the compound (XI), may be prepared in a manner similar to either one of the above-described Processes A-1, A-7. It may also be prepared by reacting the compound (IX) with a compound represented by the formula, HO--(CH 2 ) m OH, in a manner similar to the above-described Process C.
• the compound (I) of this invention is obtained. It is preferred to use imidazole as its alkali metal salt.
• pyridine as pyridyl lithium, which is obtained for example by reacting n-butyl lithium with bromopyridine at -35° C., a pyridylalkyl lithium obtained in the same manner, or the like.
• the reaction may advantageously proceed by carrying it out in an inert solvent, for example, ether or tetrahydrofuran, at a temperature of -80°--30° C., for several minutes to 1 hour.
• the starting compounds (XIII) for Process D may be prepared (1) in a manner similar to either one of the above-described Processes A-1-A-7, (2) by reacting the compound (IX) with a compound represented by the formula, ##STR13## in a manner similar to Process B, or (3) by reacting the compound (XI) with a compound represented by the formula, HOCO--A--Hal, in a manner similar to Process C.
• the compound (I) of this invention may also be obtained by using an N-protected compound of the compounds (IX), (XI) or (XIII) and, after effecting the corresponding reaction, by removing the protecting group.
• the protecting group may be example be used a methoxymethyl group, ethoxymethyl group or the like. These protecting groups can be easily removed by hydrolysis or the like after completion of the reaction.
• the thus-obtained compounds (I) of this invention may be converted, in accordance with methods known per se in the art, into their inorganic or organic acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, oxalates, acetates, citrates, maleates, tartrates, etc.
• inorganic or organic acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, oxalates, acetates, citrates, maleates, tartrates, etc.
• the compounds of this invention have extremely strong thromboxane A 2 formation inhibitory effects.
• the compounds of this invention have hyperkinemic effects for the coronary and vertebral arteries. Their advantageous feature is that they can show such effects over prolonged periods of time. Although they increase the amount of blood which flows through the coronary artery, they have another advantageous feature that they show weak heart-beat increasing effects.
• liquid or solid carriers or diluents may be used.
• these carriers may be mentioned various excipients, binders, lubricants, emulsifiers, etc., which are by themselves known in the field of production of pharmaceutical compositions.
• Illustrative of carriers or diluents may include starches such as potato starch, wheat starch, corn starch and rice starch; saccharides such as lactose, sucrose, glucose, mannitol and sorbitol; celluloses such as crystalline cellulose, calcium carboxycellulose and moderately-substituted hydroxypropylcellulose; inorganic materials such as potassium phosphate, calcium sulfate, calcium carbonate and talc; binders such as gelatin, gum arabic, methylcellulose, sodium carboxymethylcellulose, polyvinyl pyrrolidone and hydroxypropylcellulose; anionic surfactants of the polyhydric alcohol ester type, such as fatty acid monoglycerides, sorbitan fatty acid esters, sucrose and polyglycerol fatty acid esters; anionic surfactants of the polyoxyethylene type; and so on.
• starches such as potato starch, wheat starch, corn starch and rice starch
• saccharides such as lacto
• compositions may be processed into any pharmaceutically-known dosable forms such as suppositories, powder, granules, tablets, troches, liquid preparations, injectable preparations, suspensions, etc.
• compositions of the compounds of this invention may be administered in any route, namely, orally, or parenterally, e.g., intravenously, sublingally or via the rectum. Oral administration is however preferred when administered for long periods of time.
• Dose may be subject to variations as needed.
• the compounds (I) of this invention may each be administered at a dose of about 1-500 mg/body/day with 50-200 mg/body/day being preferred.
• the acute toxicity levels (LD 50 ) of the compounds of this invention are about 300 mg/kg (rat) when administered orally and 30-50 mg/kg (rat) when administered intravenously. Their toxicity levels are hence extremely low.
• N,N-dimethylformamide solution containing 200 mg of 4-(1-imidazolylmethyl)cinnamic acid, 213 mg of N,N'-carbonyldiimidazole was added. The resultant mixture was stirred at room temperature for 80 minutes.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=15889265

Family Applications (1)

Country Status (10)

Cited By (4)

Families Citing this family (1)

Citations (2)

Family Cites Families (8)

• 1984
  • 1984-08-14 JP JP59169588A patent/JPS6147477A/ja active Granted
• 1985
  • 1985-08-12 AU AU47217/85A patent/AU577152B2/en not_active Ceased
  • 1985-08-12 HU HU853611A patent/HU195500B/hu not_active IP Right Cessation
  • 1985-08-12 EP EP19850904021 patent/EP0190364A4/en not_active Withdrawn
  • 1985-08-12 US US06/851,134 patent/US4737506A/en not_active Expired - Fee Related
  • 1985-08-12 KR KR860700209A patent/KR860700252A/ko not_active Application Discontinuation
  • 1985-08-12 WO PCT/JP1985/000449 patent/WO1986001206A1/ja not_active Application Discontinuation
  • 1985-08-14 ES ES546136A patent/ES8707185A1/es not_active Expired
• 1986
  • 1986-04-11 DK DK165686A patent/DK165686D0/da not_active IP Right Cessation
  • 1986-04-11 NO NO861422A patent/NO861422L/no unknown
• 1987
  • 1987-02-09 ES ES557372A patent/ES8801206A1/es not_active Expired
  • 1987-02-09 ES ES557371A patent/ES8802512A1/es not_active Expired

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events